HIVEP3 expression was augmented in the elder age groups, non‐APL subtypes, subgroups with poor or complex cytogenetic abnormalities, and patients without PML‐RAR fusion or IDH‐R132 mutation, which coincided with the worse outcomes based on risk stratification. Here, HIVEP3 is linked to acute promyelocytic leukemia.